Is elabela/toddler a poor prognostic marker in heart failure patients?

No abstract is available for this paper.

• Publication year

  2023

• Venue

  Hippokratia

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 39372325PMCID PMC11451502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impact of NT-proBNP on prognosis of acute decompensated chronic heart failure versus de novo heart failure.

  2022cited by this paper
• The natriuretic peptide system in heart failure: Diagnostic and therapeutic implications.

  2021cited by this paper
• Left ventricular dimensions and cardiovascular outcomes in systolic heart failure: the WARCEF trial

  2021influential reference
• The Elabela-APJ axis: a promising therapeutic target for heart failure

  2020cited by this paper
• Apelin/Elabela-APJ: a novel therapeutic target in the cardiovascular system

  2020cited by this paper
• N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study.

  2020cited by this paper
• Recombinant Fc-Elabela fusion protein has extended plasma half-life andmitigates post-infarct heart dysfunction in rats.

  2019cited by this paper
• Left atrial diameter in heart failure with left ventricular preserved, mid-range, and reduced ejection fraction

  2019cited by this paper
• Elabela, a newly discovered APJ ligand: Similarities and differences with Apelin

  2018cited by this paper
• Will Biomarkers Succeed as a Surrogate Endpoint in Heart Failure Trials?

  2018cited by this paper
• ELABELA-APJ axis protects from pressure overload heart failure and angiotensin II-induced cardiac damage

  2017cited by this paper
• Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension

  2017cited by this paper
• Alternative Progenitor Cells Compensate to Rebuild the Coronary Vasculature in Elabela- and Apj-Deficient Hearts.

  2017cited by this paper
• Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions.

  2016cited by this paper
• Pharmacological Strategies to Retard Cardiovascular Aging.

  2016cited by this paper
• Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

  2015cited by this paper
• The renin-angiotensin-aldosterone system and heart failure.

  2014cited by this paper
• Left Ventricular Diameter and Risk Stratification for Sudden Cardiac Death

  2014cited by this paper
• Sustained Cardiovascular Actions of APJ Agonism During Renin–Angiotensin System Activation and in Patients With Heart Failure

  2013cited by this paper
• ELABELA: a hormone essential for heart development signals via the apelin receptor.

  2013influential reference
• Increased left atrial volume index predicts a poor prognosis in patients with heart failure.

  2011cited by this paper
• Pathophysiology of heart failure

  2010cited by this paper
• Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure

  2010cited by this paper
• Apelin increases contractility in failing cardiac muscle.

  2006cited by this paper
• Pathophysiology of Heart Failure

  1996cited by this paper
• Assessment of left ventricular function by the midwall fractional shortening/end-systolic stress relation in human hypertension.

  1994cited by this paper
• Cardiac troponin-I: a biochemical marker for cardiac cell necrosis.

  1993cited by this paper

• ELABELA: a polypeptide with therapeutic potential in cardiovascular diseases

  2025cites this paper